Evaluation of a recombinant vaccinia virus containing pseudorabies (PR) virus glycoprotein genes gp50, gII, and gIII as a PR vaccine for pigs.

Virology Swine Research Unit, Agricultural Research Service, Ames, Iowa.
Archives of Virology (Impact Factor: 2.39). 09/1994; 134(3-4):259-69. DOI: 10.1007/BF01310565
Source: PubMed


Pigs vaccinated twice intramuscularly with a highly attenuated strain of vaccinia virus (NYVAC) containing gene inserts for pseudorabies virus (PRV) glycoproteins gp50, gII, and gIII produced neutralizing antibodies for PRV and were less clinically affected than were nonvaccinated pigs following oronasal exposure to virulent PRV. Also, following oronasal exposure to virulent PRV the duration of virulent virus shedding by pigs that had been vaccinated intramuscularly with the recombinant virus was statistically less (p < 0.05) than that of nonvaccinated pigs and like that of pigs vaccinated twice intramuscularly with inactivated PR vaccine. Intramuscular vaccination with the recombinant virus was compatible with the most commonly used differential diagnostic tests, namely those based on PRV glycoproteins gX and gI. Serum antibodies for these glycoproteins were absent from the sera of all pigs before and after vaccination with recombinant virus; whereas, they were present in the sera of all of the same pigs after they were exposed to virulent PRV. In contrast to the effectiveness of the recombinant virus administered intramuscularly, neither serum antibody nor clinical protection against PRV was detected when aliquots of the same recombinant virus preparation were administered either orally or intranasally. The latter finding suggests that recombinant virus replicates poorly, if at all, at these sites. If so, the dissemination of recombinant virus from vaccinated pigs to nonvaccinated pigs or other animals in contact seems unlikely.

Download full-text


Available from: Susan Brockmeier, Apr 01, 2014
  • Source
    • ") that are implicated in the processes of virus entry and cell-to-cell spread (Rauh & Mettenleiter, 1991 ; Peeters et al., 1992). PrV gB plays an important role in inducing protective immunity (Marchioli et al., 1988 ; Riviere et al., 1992 ; Nakamura et al., 1993 ; Mengeling et al., 1994 ; Xuan et al., 1995) and is considered to be a promising candidate for a subunit vaccine. At present, there are few data concerning the distribution of antigenic and immunogenic regions throughout the PrV gB molecule. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In order to map antigenically important regions of glycoprotein B (gB) of pseudorabies virus (PrV), a panel of recombinant fragments of gB expressed in E. coli and truncated fragments of gB generated by cleavage of purified native gB with trypsin and cyanogen bromide was analysed by using 26 monoclonal antibodies directed against gB. Three continuous epitopes were localized in the vicinity of the N terminus of gB, between amino acids (aa) 59 and 126. One continuous epitope mapped between residues 214 and 279. The residues involved in the assembly of eight discontinuous epitopes were located between aa 540 and 734. The constituents of two discontinuous epitopes were harboured in a segment encompassing aa 540-646. The clustering of continuous epitopes at the extreme N terminus of PrV gB and the locations of residues involved in the assembly of discontinuous epitopes of PrV gB are in good agreement with data on epitope locations in gB homologues from other herpesviruses.
    Journal of General Virology 04/1999; 80 ( Pt 3)(3):537-41. DOI:10.1099/0022-1317-80-3-537 · 3.18 Impact Factor
  • Source
    • "The piglets were left in the isolation room in which they farrowed until the end of the experiment. Based on past studies we have found no transmission of the NYVAC vector to occur between vaccinated and nonvaccinated animals (Mengeling et al., 1994 and unpublished data). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Piglets which had received colostral antibody to pseudorabie virus (PRV) were divided into four groups and inoculated with a NYVAC vaccinia recombinant expressing glycoprotein gD of PRV, a NYVAC recombinant expressing glycoprotein gB of PRV, an inactivated PRV vaccine, or no vaccine. The piglets were vaccinated twice, 3 weeks apart, beginning at approximately 2 weeks of age and later challenged with virulent PRV oronasally. All three vaccines protected similarly when no maternal antibody was present. Although all three vaccines induced some active immunity in piglets with maternal antibody, piglets receiving the NYVAC/gB vaccine were the only ones protected similarly whether or not they had maternal antibodies to PRV.
    Veterinary Microbiology 12/1997; 58(2-4):93-103. DOI:10.1016/S0378-1135(97)00161-2 · 2.51 Impact Factor
  • Source
    • "ierte gD - exprimierende immortalisierte Säugerzellen ( Marchioli et al . , 1987 ) , gB - exprimierendes Baculovirus ( Xuan et al . , 1995 ) , Adenovirus , das gD exprimiert ( Adam et al . , 1994 ; Eloit et al . , 1990 ; Hammond et al . , 2001 ; Monteil et al . , 2000 ) und Vacciniavirus , das gB , gC und gD exprimiert ( Marchioli et al . , 1987 ; Mengeling et al . , 1994 ; Riviere et al . , 1992 ) getestet . Glykoprotein gB ( Nakamura et al . , 1993 ; Xuan et al . , 1995 ) , Glykoprotein gD ( Ishii et al . , 1988 ) und anti - Idiotyp - anti - gD Antikörper ( Tsuda et al . , 1992 ) wurden als Subunitvakzine verabreicht ."
    [Show abstract] [Hide abstract]
    ABSTRACT: Zugl.: Tübingen, Univ., Diss., 2004.
Show more